Garry A. Nicholson serves as Independent Chairman of the Board of the Company. Mr. Nicholson has more than 30 years of pharmaceutical and biotech oncology experience. From August 2015 to November 2016, he served as President and Chief Executive Officer of XTuit Pharmaceuticals, where he also was a member of the board of directors. During the time period of May 2008 through April 2015, he led the global oncology franchise at Pfizer in the role of President, Pfizer Oncology. His responsibilities included global commercialization and sales, clinical development and regulatory strategy, and business development. Under his leadership, the company developed and launched Ibrance® (palbociclib), the first CDK4/6 inhibitor approved in the U.S. and Europe. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company’s Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Earlier in his career, Mr. Nicholson held various leadership positions in the oncology division of Eli Lilly and Company. In addition, he has served as an advisor to AMPATH, a consortium of North American universities and health centers, Moi University, Moi Teaching and Referral Hospital, and the Government of Kenya, which helps build sustainable healthcare systems in developing nations. Mr. Nicholson began his career in healthcare as a staff pharmacist at Emory University. He currently serves on the board of directors of Five Prime Therapeutics, Inc., a publicly traded clinical stage pharmaceutical company, Personal Genome Diagnostics Inc., a privately held cancer genomics company, SQZ Biotechnologies, Inc., a privately held biotechnology company and Tmunity Therapeutics Inc., a privately held biotechnology company.
As the Independent Chairman of the Board of G1 Therapeutics Inc, the total compensation of Garry Nicholson at G1 Therapeutics Inc is $1,512,540. There are 4 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.
Garry Nicholson is 65, he's been the Independent Chairman of the Board of G1 Therapeutics Inc since 2019. There are 2 older and 23 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
Garry's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
G1 Therapeutics Inc executives and other stock owners filed with the SEC include: